Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D. P. Devanand

Showing results (191-200 of 215) with videos related to

Pageof 22
Sort By:
The American Journal of Psychiatry|November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of HallucinationsAnjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Journal of Geriatric Psychiatry and Neurology|May 1, 2010
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controlsD P Devanand, Arthur Mikhno, Gregory H Pelton, et al.
Nutrients|November 14, 2023
BMI Increases in Individuals with COVID-19-Associated Olfactory DysfunctionBrandon J Vilarello, Patricia T Jacobson, Jeremy P Tervo, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|June 10, 2024
Recovery rates of persistent post-COVID-19 olfactory dysfunction using psychophysical assessment: A longitudinal cohort studyJeremy P Tervo, Patricia T Jacobson, Brandon J Vilarello, et al.
International Psychogeriatrics|October 15, 2014
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definitionJeffrey Cummings, Jacobo Mintzer, Henry Brodaty, et al.
BMJ Open|February 9, 2020
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trialD P Devanand, Howard Andrews, William C Kreisl, et al.
Translational Psychiatry|December 10, 2015
Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688C DeLorenzo, J Sovago, J Gardus, et al.
Journal of Alzheimer'S Disease : JAD|October 7, 2017
Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and CognitionBabette L R Reijs, Inez H G B Ramakers, Lyzel Elias-Sonnenschein, et al.
The Journal of ECT|August 31, 2001
Treatment of the modal patient: does one size fit nearly all?H A Sackeim, D P Devanand, S H Lisanby, et al.
Rhinology|July 1, 2024
COVID-19 olfactory dysfunction: associations between coping, quality of life, and mental healthP T Jacobson, B J Vilarello, C Snyder, et al.
Pageof 22

Showing results (191-200 of 215) with videos related to

Sort By:
Pageof 22
The American Journal of Psychiatry|November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of HallucinationsAnjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Journal of Geriatric Psychiatry and Neurology|May 1, 2010
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controlsD P Devanand, Arthur Mikhno, Gregory H Pelton, et al.
Nutrients|November 14, 2023
BMI Increases in Individuals with COVID-19-Associated Olfactory DysfunctionBrandon J Vilarello, Patricia T Jacobson, Jeremy P Tervo, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|June 10, 2024
Recovery rates of persistent post-COVID-19 olfactory dysfunction using psychophysical assessment: A longitudinal cohort studyJeremy P Tervo, Patricia T Jacobson, Brandon J Vilarello, et al.
International Psychogeriatrics|October 15, 2014
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definitionJeffrey Cummings, Jacobo Mintzer, Henry Brodaty, et al.
BMJ Open|February 9, 2020
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trialD P Devanand, Howard Andrews, William C Kreisl, et al.
Translational Psychiatry|December 10, 2015
Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688C DeLorenzo, J Sovago, J Gardus, et al.
Journal of Alzheimer'S Disease : JAD|October 7, 2017
Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and CognitionBabette L R Reijs, Inez H G B Ramakers, Lyzel Elias-Sonnenschein, et al.
The Journal of ECT|August 31, 2001
Treatment of the modal patient: does one size fit nearly all?H A Sackeim, D P Devanand, S H Lisanby, et al.
Rhinology|July 1, 2024
COVID-19 olfactory dysfunction: associations between coping, quality of life, and mental healthP T Jacobson, B J Vilarello, C Snyder, et al.
Pageof 22